CXCL14 and head and neck squamous cell carcinoma: Our research findings reveal that caudal type homeobox 2 (CDX2), upstream regulator of CXCL14, activates CXCL14 enhancer to up‐regulate its expression and enhance the therapeutic efficacy of immunotherapy against HNSCC by NK cells.